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Abstract 
A simple, rapid, accurate and precise UV method was developed and validated for the estimation of 
Itraconazole in pharmaceutical dosage form. Spectroscopic method was carried out by using acidic ethanol as solvent. 
Itraconazole detection wavelength was set at 262nm for validation purpose linearity, accuracy, repeatability, precision, 
LOD, LOQ, and ruggedness parameters were studied. The linearity was found to be in the range of 2-12 µg/ml. 
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1. Introduction 
UV spectroscopy involves the promotion of 
electrons from the ground state to higher energy state. It 
is very useful to measure the number of conjugated 
double bonds and also aromatic conjugation within the 
various molecules. For visible and ultra-violet spectrum, 
electronic excitation occurs in the range 200-800 nm and 
involves the promotion of electrons to the higher energy 
molecule orbital.  
A record of the amount of light absorbed by 
sample as a function of the wavelength of light in nm 
units is called absorption spectrum which is generally 
consist of absorption bonds. UV spectroscopy is based on 
absorption law in which absorption of light by the 
molecules. These are 
1. Lambert’s law  
2. Beer’s law    
Lambert’s law: “When a beam of monochromatic 
radiation passes through a homogeneous absorbing 
medium, the rate of decrease of intensity of radiation with 
thickness of absorbing medium is proportion to the 
incident radiation.” Mathematically, law is expressed as 
;  
Beer’s law: “When a beam of monochromatic radiation 
is passed through a solution of an absorbing substance, 
the rate of decrease of intensity of radiation with 
thickness of absorbing solution is proportion to the 
intensity of incident radiation as well as the concentration 
of solution.” 
Mathematically, law is expressed as;  
Validation: 
Validation yields a developed process, the 
product of which should do what the user expects it to do. 
It is nothing but reproducibility of result validation 
according to various agencies is spelled as ; As per FDA. 
“Validation is defined as the collection and 
evaluation of data from the process design stage 
throughout production, in which establishes scientific 
evidence that a process is capable of consistently 
delivering quality product.” 
As per WHO – The documented act of providing 
that any procedure, process, equipment, activity or system 
actually leads to the expected result. 
Analytical Validation: 
Validation of analytical method may be defined 
as “The process by which it is established, by laboratory 
studies, that the performance characteristics of the 
method meet the requirement for the intended analytical 
application”.  
One of the triazole antifungal agent that inhibit 
cytochrome P-450 dependent enzyme resulting in 
impairment of ergosterol synthesis. It has been used 
against histoplasmosis, blastomycosis, cryptococcal 
meningitis and aspergillosis. 
Itraconazole is a synthetic triazole antifungal 
agent. Itraconazole is a 1:1:1:1 racemic mixture of four 
diastereomers (two enantiomeric pairs), each possessing 
three chiral centers. It may be represented by the 
following nomenclature: 4-[4-[4-[4-[[2-(2, 4-
dichlorophenyl)- 2- (1H- 1, 2, 4- triazol- 1-ylmethyl)- 
1,3- dioxolan- 4- yl] methoxy]phenyl] piperazin-1- 
yl]phenyl]-2-(1-methylpropyl)-2, 4-dihydro-1, 2, 4-
triazol- 3-one (Fig 1). It has a molecular formula is 
C35H38Cl2N8O4 and a molecular weight is 705.64. [1-
4] It is a white to slightly yellowish powder. It is very 
slightly soluble in alcohols, and freely soluble in 
dichloromethane. Itraconazole is highly lipophilic in 
nature and practically insoluble in water. It is an 
extremely weak base (pKa =3.7) that is ionized only at 
very low pH. It is a hydrophobic anti mycotic drug with 
three chiral centers and is used clinically as a stereo 
isomeric mixture. [5] It is an orally active triazole 
antifungal agent, which demonstrates broad spectrum 
activity against a number of fungal species including 
dermatophytes, Malassesia further, Candida species, 
Aspergillus species, and Histoplasma capsulatum var. 





capsulatum. [6,7] The mechanism of action of 
itraconazole is it interacts with 14-α demethylase, a 
cytochrome P-450 enzyme necessary to convert 
lanosterol to ergosterol. As ergosterol is an essential 
component of the fungal cell membrane, inhibition of its 
synthesis results in increased cellular permeability 
causing leakage of cellular contents. Itraconazole may 
also inhibit endogenous respiration, interact with 
membrane phospholipids, inhibit the transformation of 
yeasts to mycelial forms, inhibit purine uptake, and 
impair triglyceride and/or phospholipid biosynthesis. 
Itraconazole is metabolized predominately by the 
cytochrome P450 3A4 isoenzyme system (CYP3A4) in 
the liver, resulting in the formation of several metabolites, 
including hydroxyl itraconazole, the major metabolite. [8] 
Its oral bioavailability was found to increase when taken 
with food, with plasma concentration approximately two 
times that taken in the fasting state. [9] It is extensively 
metabolized in the liver, mainly via an oxidative pathway, 
into the bioactive metabolite hydroxyl itraconazole. [10]  
Itraconazole was formulated into several 
pharmaceutical forms through various routes of 
administration. Itraconazole capsules are used to treat 
fungal infections in the lungs that can spread throughout 
the body. Used to treat fungal infections of the 
fingernails. Tablets and capsules are used to treat fungal 
infections of the toenails. Itraconazole oral solution 
(liquid) is used to treat yeast infections of the mouth and 
throat or of the esophagus (tube that connects the throat to 
the stomach) [11] Several HPLC [12], and LC/MS-MS 
[13-15] methods have been reported for the analysis of 
Itraconazole in plasma that suffer from either undesirably  
 
Need and objective of work:  
1. To develop and validate analytical method of 
Itraconazole capsule. 
2. The development and validation of simple, accurate 
and precise analytical method of Itraconazole in bulk 
drug and in pharmaceutical dosage forms by UV-
Visible spectrophotometric method.  
 
2. Materials and methods: 
` Itraconazole bulk drug and capsule 
(CANDIFORCE 100) purchased from market, 
Hydrochloric acid and ethanol obtained from college. 
2.1 Instrument 
UV spectrophotometric method was performed 
on double beam UV-visible spectrophotometer 
(Shimadzu, model 1800) having two matched quartz cells 
with 1 cm light path.  
 
Figure 2 Instrument: UV-Visible spectrophotometer 
2.2 Methodology 
2.2.1 Selection of solvent  
Acidic ethanol was selected as ideal solvent for 
spectrophotometric analysis of Itraconazole 
2.2.2 Preparation of standard stock solution 
(1000μg/ml) 
Accurately weighed 100 mg Itraconazole was 
volumetric flask and dissolved and diluted up to the mark 
with 0.1N acidic ethanol to give a stock solution having 
strength 1000μg/ml.100 μg/ml working standard solution 
was prepared by diluting 1 ml of stock solution to 10 ml 
with 0.1N acidic ethanol. 
2.2.3 Preparation of (100μg/ml) 
To measure the Itraconazole content of capsule 
(label claim100 mg Itraconazole per capsule, Itaspor 
capsules), twenty capsules were weighed, the mean 
weight was determined. A weight of the powder 
equivalent to100 mg Itraconazole was transferred to a 100 
ml volumetric flask containing 50 ml 0.1N acidic ethanol 
and the mixture was sonicated for 30 min then diluted to 
100 ml with0.1N acidic ethanol (1000 μg/ml). The 
solution was filtered and 1 ml of filtered solution was 
diluted tenfold to furnish a concentration of 100μg/ml. 
2.2.4 Validation of UV spectrophotometric method 
Determination of wavelength  
The stock solution was diluted with acidic 
ethanol to obtain solution of concentration 10μg/ml. the 
absorbance of resulting solution was scanned in UV 
spectrometer under the range of 200- 400nm.the 
absorbance maximum was found at wavelength about 
262nm. 
 
Figure 3: UV Spectra of Itraconazole 





Linearity and range 
The linearity was determined by analyzing 6 
independent levels of calibration curve in the range of 2-
12μg/ml. Absorbance of each solution against methanol 
was recorded at curve of absorbance vs. concentration 
was plotted and correlation co-efficient and regression 
line equation for Itraconazole were determined. 
 
Table 1: Linearity 
 
Sr. No. Concentration Absorbance 
1 0 0.001 
2 2 0.109 
3 4 0.196 
4 6 0.259 
5 8 0.330 
6 10 0.444 
7 12 0.517 
 
 
Figure 4: linearity curve of Itraconazole 
Accuracy 
Accuracy was determined by performing 
recovery studies by spiking different concentrations of 
pure drug in the pre-analyzed powder for infusion 
samples within the analytical concentration range of the 
proposed method at three different set at level of 80%, 
100% and 120%. The amount of Itraconazole was 
calculated at each level and % Recoveries were 
computed. 
 
Table 2: Accuracy 1 
80% 
Sr no. Conc. Amount added Abs. Amount found Amount Recovered % Recovered 
1 6 4.8 0.207 4.60 4.82 100.36 
2 6 4.8 0.205 4.55 4.77 99.37 
3 6 4.8 0.206 4.57 4.79 99.87 
   
Mean 4.57 4.79 99.87 
   
SD 0.02 0.02 0.50 
   
%RSD 0.52 0.50 0.50 
 
Table 3: Accuracy 2 
100% 
Sr no. Conc. Amount added Abs. Amount found Amount Recovered % Recovered 
1 6 6 0.259 5.83 6.06 100.93 
2 6 6 0.258 5.81 6.03 100.53 
3 6 6 0.258 5.81 6.03 100.53 
   
Mean 5.82 6.04 100.66 
   
SD 0.01 0.01 0.23 
   
%RSD 0.24 0.23 0.23 
 
Table 4: Accuracy 3 
120% 
Sr no. Conc. Amount added Abs. Amount found Amount Recovered % Recovered 
1 6 7.2 0.31 7.05 7.27 100.97 
2 6 7.2 0.309 7.02 7.25 100.64 
3 6 7.2 0.314 7.14 7.37 102.29 
   
Mean 7.07 7.29 101.30 
   
SD 0.06 0.06 0.87 
   
%RSD 0.89 0.86 0.86 
  
Precision 
Intra-day precision was determined by analyzing 
Itraconazole (2-6μg/ml) at three different time points of 
the same day and determined by analyzing Itraconazole 
(2-6μg/ml) at three different time points on different days 









Table 5: Intraday Precision 
Sr. No. Conc. Abs. I II III MEAN  SD %RSD 
1 2 0.111 0.107 0.109 0.11 0.00 1.83 
2 4 0.2 0.206 0.206 0.20 0.00 1.70 
3 6 0.263 0.257 0.259 0.26 0.00 1.18 
 
Table 6: Interday Precision 
Sr. No. Conc. Abs. I II III MEAN  SD %RSD 
1 2 0.101 0.1 0.102 0.10 0.00 0.99 
2 4 0.133 0.13 0.131 0.13 0.00 1.16 
3 6 0.163 0.157 0.159 0.16 0.00 1.91 
Repeatability 
Repeatability was carried out by using a minimum of 6 determinations at one of the test concentration. 
Table 6: Repeatability 
Sr. No. Conc. Peak Area Amt Found %Amt Found 
1 6 0.262 5.90 98.41 
2 6 0.263 5.93 98.81 
3 6 0.262 5.90 98.41 
4 6 0.263 5.93 98.81 
5 6 0.261 5.88 98.02 
6 6 0.265 5.98 99.60 
  
Mean 5.92 98.68 
  
SD 0.03 0.54 
  
%RSD 0.55 0.55 
 
LOD AND LOQ 
Detection limit was determined based on the 
standard deviation of the response & slope of calibration 
curve. 
 
LOD= 3.3*σ/S and LOQ= 10*σ/S 
Where, 
σ = the standard deviation of y-intercepts of regression lines 
S = the slope of the calibration curve
Table 7:  LOD AND LOQ 
Sr. No.  Conc. Area I II III Mean SD %RSD 
1 2 0.109 0.105 0.108 0.11 0.00 1.94 
2 4 0.198 0.199 0.192 0.20 0.00 1.93 
3 6 0.269 0.279 0.271 0.27 0.01 1.94 
4 8 0.375 0.388 0.387 0.38 0.01 1.89 
5 10 0.444 0.432 0.428 0.43 0.01 1.92 
6 12 0.517 0.498 0.509 0.51 0.01 1.88 
          Avrg SD 0.01   
 
LOD = 3.3 * Avrg SD/ Slope 0.785 
LOQ = 10 * Avrg SD / Slope 2.38 
Ruggedness  
The evaluation of Ruggedness should be 
considered during the development phase and depends on 
the type of procedure under study. It should show the 
reliability of an analysis with respect to external factors in 
method parameters such as instrument, analyst variation. 




 Sr. No. Conc. Area Sr. No. Conc. Area 
1 6 0.258 1 6 0.256 
2 6 0.256 2 6 0.262 
3 6 0.265 3 6 0.253 
4 6 0.256 4 6 0.256 
5 6 0.258 5 6 0.258 
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Robustness  
Robustness is determined by making small but 
deliberate variations in method parameters. The 
evaluation of robustness should be considered during the 
development phase and depends on the type of procedure 
under study. It should show the reliability of an analysis 
with respect to deliberate variations in method parameters 
such temperature. 
  
Table 9: Robustness 
Sr. No. Temperature  Conc. Absorbance Mean  SD %RSD 
1 25 6 0.258    
2 25 6 0.256 0.26 0.00 1.82 
3 25 6 0.265    
4 30 6 0.256    
5 30 6 0.258 0.26 0.00 1.18 
6 30 6 0.262    
7 35 6 0.269    
8 35 6 0.279 0.27 0.01 1.94 
9 35 6 0.271    
 
3. Result and discussion 
The UV method has been developed for the estimation of Itraconazole in bulk & pharmaceutical dosage 
formulation. 
Table 10: Result discussion 
Sr. No. Validation Parameter Result 
1 Solubility Acidic ethanol 
2 UV detection Maximum wavelength 262 nm 
3 Linearity range 2-12 µg/ml 
4 Standard regression equation Y=0.042x+0.014 
5 Coefficient of regression (r
2
) 0.996 












10 Ruggedness (n=6) 1.28 
 
4. Conclusion 
The developed method was simple, accurate, 
precise and economic in nature and can be used for 
analysis of marketed formulations. 
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